Synnovation Starts Ph 1 SNV4818 Trial For Tumors With PI3K? Inhibitor
24 Feb 2025 //
BUSINESSWIRE
Synnovation Announces First Patient Dosed in Phase I Trial with SNV1521
11 Mar 2024 //
BUSINESSWIRE
Synnovation Launches with $102M to Advance Pipeline of Precision Therapies
24 Jan 2024 //
BUSINESSWIRE